ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2465

Reliability and Validity of the Self‐Administered Comorbidity Questionnaire in Psoriatic Arthritis

Didem Erdem1, Halise Hande Gezer 2, Sevtap Acer Kasman 1 and Mehmet Tuncay Duruoz 1, 1Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Turkey, 2Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Istanbul, Turkey

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Comorbidity, health-related quality of life and Self‐Administered Comorbidity Questionnaire, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The Self‐Administered Comorbidity Questionnaire (SCQ) is a self-report questionnaire. It assesses 13 common medical conditions and the impact of comorbidities on functional status (1). The aim of this study is to investigate the validity and reliability of the Turkish version of the SCQ in Psoriatic Arthritis (PsA).

Methods: Patients with PsA, according to Classification Criteria for Psoriatic Arthritis (CASPAR), were included in the study. Data about age, sex, body mass index (BMI), disease duration (month) were noted. Psoriatic Arthritis Quality of Life (PsAQoL) scale and Short Form 36 (SF-36) were used to assess the quality of life. The Health Assessment Questionnaire (HAQ) was used to evaluate the physical disability. The effects of comorbid diseases on quality of life (QoL) and Patient Global Assessment of General Health (PGA) were assessed on the Visual Analogue Scale (VAS). The English version of SCQ was the original scale used for translation and adaptation. Translation, back translation, and cross-cultural adaptation of the SCQ into Turkish were done according to the standard procedure. The reliability of SCQ was determined by internal consistency (Cronbach’s alpha coefficient). Face validity and construct validity (convergent and divergent validities) were evaluated. For the face validity, the final Turkish version of SCQ was tested by 15 patients to determine if they could understand the items. The correlations of the SCQ with the HAQ, SF-36, PsAQoL, the VAS scores of the effect of comorbid diseases on QoL and PGA were assessed for convergent validity. The relation of the SCQ with age, BMI, and disease duration were assessed for divergent validity. The construct validity of the SCQ scale was determined by Spearman’s correlation coefficient. The descriptive analysis was done for demographic data. P< 0.05 accepted as significant.

Results: The mean age of 65 patients (46 female, 19 male) with PsA was 46.20 (SD: 13.05) years. The median (min-max) duration of disease was 24 (1-384) months. The mean BMI of patients was 29.06 (SD: 5.92). The Cronbach’s alpha coefficient of the SCQ for internal consistency was 0.755. The SCQ score had moderate and significant positive correlations with HAQ, PsAQoL, the VAS scores of the effect of comorbidity on QoL and PGA (p< 0.05). The significant negative correlations were detected with physical function, physical role limitation, bodily pain, general health, vitality and social function subgroups of the SF-36 (p< 0.05). The SCQ score had positive correlations with age and BMI (p< 0.05). There was no correlation between SCQ score and duration of disease (rho: 0.164, p: 192). The correlations of SCQ with the clinical variables that show convergent and divergent validities were given in Table 1.

Conclusion: The Turkish version of the SCQ is a valid and reliable instrument in PsA. The SCQ is a simple, accurate and not time-consuming self-report instrument to assess comorbidities in patients with PsA.

Reference:

1. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003; 49(2):156-63.

Table 1. Construct validity of SCQ -Correlation coefficient with other parameters-


Disclosure: D. Erdem, None; H. Gezer, None; S. Acer Kasman, None; M. Duruoz, İbrahim etem, 8, Abdi İbrahim, 8, Abdi Ibrahim, 8, Abvie, 2, 8, AMGEN, 8, AMGEN, Novartis, ILKO, ONKO, İbrahim Ethem, Abdi İbrahim, 8, Ibrahim Ethem, 8, ILKO, 8, Novartis, 8, ONKO, 8.

To cite this abstract in AMA style:

Erdem D, Gezer H, Acer Kasman S, Duruoz M. Reliability and Validity of the Self‐Administered Comorbidity Questionnaire in Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/reliability-and-validity-of-the-self%e2%80%90administered-comorbidity-questionnaire-in-psoriatic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reliability-and-validity-of-the-self%e2%80%90administered-comorbidity-questionnaire-in-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology